Artwork

Sisällön tarjoaa Lauren Freedman (she/her). Lauren Freedman (she/her) tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!

137: Lyfebulb Founder Dr. Karin Hehenberger

1:08:09
 
Jaa
 

Manage episode 304533256 series 2559819
Sisällön tarjoaa Lauren Freedman (she/her). Lauren Freedman (she/her) tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.

Dr. Karin Hehenberger has close to 20 years of experience in the life sciences sector. She served as an executive at Eyetech Pharmaceuticals and Coronado BioSciences, and had strategic management roles at Johnson & Johnson (Vice President, Metabolic Strategy), JDRF (Senior Vice President, Strategic Alliances), and McKinsey; as well as senior partnership roles at public (Brummer & Partners) and private (Scandinavian Life Science Ventures) multibillion-dollar investment funds. She received her MD and PhD degrees from the Karolinska institute, and did her post-doctoral fellowship as a JDRF stipend recipient at the Joslin Diabetes Center, Harvard Medical School. Inspired by her background and diagnosis of type 1 diabetes, she is the founder and CEO of Lyfebulb.

Tune in as Karin shares:

  • that she was always in good health — but that at the age of 16, this changed
  • that shortly after, she was diagnosed with type 1 diabetes
  • the fear that came along with her diagnosis
  • what she wishes she’d done differently after her diagnosis
  • that she spent the first decade after diagnosis largely hiding it from the world, even though it played a role in shaping her career
  • that when her dad donated a kidney to her 12 years ago, doctors also suggested she get a pancreas transplant simultaneously
  • what qualifies diabetes patients for pancreas transplants
  • how she recognized that patients can be innovators — and how this inspired her to launch Lyfebulb
  • how she also realized that patients need patients — and how this plays into Lyfebulb’s community today
  • how she manages the side effects of her immunosuppressants
  • the importance of educating care partners in the nuances of chronic disease — and how vital it is that patients learn to ask for what they need
  • the obstacles presented by the American healthcare system
  • what it was like to entertain motherhood as a patient on immune-suppressing drugs

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit uninvisiblepod.substack.com
  continue reading

157 jaksoa

Artwork
iconJaa
 
Manage episode 304533256 series 2559819
Sisällön tarjoaa Lauren Freedman (she/her). Lauren Freedman (she/her) tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.

Dr. Karin Hehenberger has close to 20 years of experience in the life sciences sector. She served as an executive at Eyetech Pharmaceuticals and Coronado BioSciences, and had strategic management roles at Johnson & Johnson (Vice President, Metabolic Strategy), JDRF (Senior Vice President, Strategic Alliances), and McKinsey; as well as senior partnership roles at public (Brummer & Partners) and private (Scandinavian Life Science Ventures) multibillion-dollar investment funds. She received her MD and PhD degrees from the Karolinska institute, and did her post-doctoral fellowship as a JDRF stipend recipient at the Joslin Diabetes Center, Harvard Medical School. Inspired by her background and diagnosis of type 1 diabetes, she is the founder and CEO of Lyfebulb.

Tune in as Karin shares:

  • that she was always in good health — but that at the age of 16, this changed
  • that shortly after, she was diagnosed with type 1 diabetes
  • the fear that came along with her diagnosis
  • what she wishes she’d done differently after her diagnosis
  • that she spent the first decade after diagnosis largely hiding it from the world, even though it played a role in shaping her career
  • that when her dad donated a kidney to her 12 years ago, doctors also suggested she get a pancreas transplant simultaneously
  • what qualifies diabetes patients for pancreas transplants
  • how she recognized that patients can be innovators — and how this inspired her to launch Lyfebulb
  • how she also realized that patients need patients — and how this plays into Lyfebulb’s community today
  • how she manages the side effects of her immunosuppressants
  • the importance of educating care partners in the nuances of chronic disease — and how vital it is that patients learn to ask for what they need
  • the obstacles presented by the American healthcare system
  • what it was like to entertain motherhood as a patient on immune-suppressing drugs

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit uninvisiblepod.substack.com
  continue reading

157 jaksoa

Όλα τα επεισόδια

×
 
Loading …

Tervetuloa Player FM:n!

Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.

 

Pikakäyttöopas